Janux Therapeutics Confirms Candidate Nomination in Bristol Myers Squibb Partnership, Activating $35 Million Milestone Payment Janux Therapeutics, Inc. has announced a significant milestone under its strategic collaboration with Bristol Myers Squibb, marking continued progress in the development of next-generation immunotherapies.…
FORE Biotherapeutics Earns Breakthrough Therapy Designation for Plixorafenib FORE Biotherapeutics, a registration-stage biopharmaceutical company focused on developing precision therapies for cancer, has announced a significant regulatory milestone for its lead investigational therapy. The U.S. Food and Drug Administration has granted…
VDYNE Secures FDA IDE Clearance to Launch TRIVITA1 Pivotal Trial for Its Transcatheter Tricuspid Valve Replacement System VDYNE, Inc., a privately held medical device innovator focused on advancing next-generation structural heart therapies, has announced a major regulatory milestone with the…
Biogen’s Acquisition of Apellis Strengthens Immunology and Rare Disease Portfolio While Accelerating Growth and Entry into Nephrology Biogen Inc. and Apellis Pharmaceuticals (Nasdaq: APLS) have announced a definitive agreement under which Biogen will acquire Apellis in a transaction valued at…
Submissions Open for the Second Annual Thomas J. Fogarty Prize Recognizing Breakthrough Medtech Innovations Nominations are set to open on April 2, 2026, for the second annual Thomas J. Fogarty Innovation Prize, widely regarded as one of the most prestigious…
Bayer Implements U.S. Leadership Restructuring in Pharmaceuticals’ Worldwide Markets to Accelerate Growth Potential Bayer has announced a significant leadership transition within its Pharmaceuticals division, signaling a strategic move to accelerate growth and strengthen its position in the United States—one of…
Tanner Pharma Group and Biodexa Introduce Global Early Access Initiative for Patients with Familial Adenomatous Polyposis (FAP) Tanner Pharma Group, a globally recognized provider of specialty medicine access solutions, has entered into a strategic partnership with Biodexa Pharmaceuticals PLC, a…
FDA Approves Higher-Dose SPINRAZA® (Nusinersen) Regimen for Spinal Muscular Atrophy Biogen Inc. has announced a significant regulatory milestone with the approval of a new high-dose regimen of SPINRAZA (nusinersen) by the U.S. Food and Drug Administration for the treatment of…
CVS Pharmacy® Marks Opening of Its First Pharmacy-Only Location in Chicago CVS Health has announced a significant expansion of its retail pharmacy strategy with the launch of a new “pharmacy-only” store concept, marking a pivotal step in the company’s broader…
Merck Presents Phase 3 CORALreef AddOn Data for Enlicitide, Highlighting Strong LDL-C Reductions and Potential as First Oral PCSK9 Inhibitor Merck has unveiled compelling late-breaking results from its Phase 3 CORALreef AddOn study, demonstrating the potential of enlicitide decanoate, an…
Alnylam Highlights New Cardiovascular Data at ACC.26, Reinforcing Potential of RNAi Therapies in ATTR-CM and Hypertension Alnylam Pharmaceuticals has unveiled a comprehensive set of new clinical and real-world findings from its cardiovascular portfolio at the American College of Cardiology Annual…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical trial, highlighting the potential of Camzyos (mavacamten) as a transformative…